UPM Institutional Repository

Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting


Mohd-Zahid, Manali Haniti and Zulkifli, Siti Nadiah and Che Abdullah, Che Azurahanim and Lim, Jit Kang and Fakurazi, Sharida and Kah, Keng Wong and Zakaria, Andee Dzulkarnaen and Ismail, Norzila and Uskoković, Vuk and Mohamud, Rohimah and Zakaria, Zukarnain (2021) Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting. RSC Advances, 11 (26). 16131 - 16141. ISSN 2046-2069


The enhanced permeability and retention effect allows for passive targeting of solid tumours by nanoparticles carrying anticancer drugs. However, active targeting by incorporation of various ligands onto nanoparticles can provide for a more selective and enhanced chemotherapeutic effect and complement the deficiencies of the passive targeting approach. Here we report on the design of the carboxyl-terminated PEGylated gold nanoparticles (AuNPs), their functionalization with anti-CD133 monoclonal antibody (mAb) via a crosslinking reaction, and subsequent 5-fluorouracil (5-FU) drug loading. The synthesized products in the form of stable colloids were characterised using a range of physicochemical techniques, including X-ray diffraction (XRD), UV-Vis spectroscopy, transmission electron microscopy (TEM), and dynamic light scattering (DLS). Conjugation of anti-CD133 mAb onto PEGylated AuNPs was confirmed with the use of UV-Vis, BCA protein assay and fluorescence microscopy. HCT116 colorectal cancer cells abundantly expressed CD133: 92.4 ± 1.3%, as measured by flow cytometry. Whereas PEGylated AuNPs not conjugated with anti-CD133 mAb accumulated mainly at the cellular membrane, nanoparticles conjugated with anti-CD133 mAb were contained within the nuclear region of the cells. Anti-CD133 mAb conjugation facilitated the specific intracellular uptake due to specific antigen–antibody binding interaction. In vitro cytotoxicity studies on HCT116 cells showed that PEGylated AuNPs and PEGylated AuNPs-CD133 did not elicit any toxicity at any of the tested concentrations. Meanwhile, 5-FU-PEGylated AuNPs-CD133 significantly reduced the cell viability relative to the treatment with 5-FU-PEGylated AuNPs without anti-CD133 mAb conjugates (p < 0.0001). This study shows that the conjugation of nanocarriers with the anti-CD133 antibody improves the specific targeting of 5-FU against colorectal cancer cells. These results demonstrate that simultaneous functionalisation of PEGylated AuNPs with antibodies and chemotherapeutic drugs is a viable strategy to combat cancer through targeted drug delivery.

Download File

[img] Text (Abstract)

Download (111kB)

Additional Metadata

Item Type: Article
Divisions: Faculty of Medicine and Health Science
Faculty of Science
Institute of Advanced Technology
DOI Number: https://doi.org/10.1039/D1RA01093J
Publisher: RSC Publishing
Keywords: Tumour; Cancer; Antibody; Drug; Chemotherapeutic
Depositing User: Ms. Nuraida Ibrahim
Date Deposited: 27 Jul 2022 08:44
Last Modified: 27 Jul 2022 08:44
Altmetrics: http://www.altmetric.com/details.php?domain=psasir.upm.edu.my&doi=10.1039/D1RA01093J
URI: http://psasir.upm.edu.my/id/eprint/97460
Statistic Details: View Download Statistic

Actions (login required)

View Item View Item